Eli Lilly (LLY) and Amgen (AMGN) filed a complaint Friday against the US Department of Health and Human Services, alleging that the agency unlawfully certified and recertified clinics that treat sexually transmitted diseases to participate in a federal drug discount program.
The plaintiffs said in the lawsuit that the court "should set aside the agency's unlawful certifications and recertifications of these ineligible entities and enjoin the agency from certifying or recertifying these entities in the future."
The Department of Health and Human Services did not immediately reply to a request for comment from MT Newswires.
Price: 791.19, Change: +23.43, Percent Change: +3.05
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.